@article { author = {Batra, Mahesh Kumar and Khan, Kamran and Saghir, Tahir and Rai, Lajpat and Sial, Jawaid and Kumar, Rajesh and Mengal, Muhammad and Saqib, Omer and Khan, Naveedullah and Khowaja, Sanam and Rizvi, Nadeem Hasan and Qamar, Nadeem and Achakzai, Abdul Samad and Kumar, Ashok and Karim, Musa}, title = {Outcomes of STEMI Complicated by Cardiogenic Shock With and Without IABP}, journal = {Iranian Heart Journal}, volume = {24}, number = {1}, pages = {69-77}, year = {2023}, publisher = {Iranian Heart Association}, issn = {}, eissn = {}, doi = {}, abstract = {Background: The results of the IABP-SHOCK II trial did not encourage the use of an intra-aortic balloon pump (IABP) in cardiogenic shock (CS) with ST-elevation myocardial infarction (STEMI). We aimed to determine whether these findings may be applicable to our population in the South Asian region, as there is a paucity of data.   Methods: In this prospective cohort study, 2 independent cohorts of STEMI patients with CS were recruited based on the utilization of IABP during revascularization. The primary endpoints of in-hospital and after 30 days of major adverse cardiac events (MACE) and the secondary endpoint of any major bleed were compared between the 2 cohorts.   Results: In total, each cohort consisted of 130 patients. Demographic, clinical, and angiographic profiles were comparable in the 2 cohorts. In the IABP and non-IABP cohorts, the in-hospital and 30-day mortality rates were 19.2% vs 26.2%; P=0.183 and 30.8% vs 36.9%; P=0.358, respectively, while the MACE rates were 20.8% vs 26.2%; P=0.306 and 32.3% vs 36.9%; P=0.434, respectively. Cardiac catheterization laboratory death was 0.8% vs 5.4%; P=0.031 and the major bleed was 4.6% vs 3.8%; P=0.758, among patients managed with IABP and without IABP, respectively.   Conclusions: Our study concluded that while there was no significant difference in the overall outcome, there was a lower trend in in-hospital mortality and significantly lower cardiac catheterization laboratory death with the use of IABP. However, the in-hospital and 30-day MACE were comparable in both groups. (Iranian Heart Journal 2023; 24(1): 69-77)}, keywords = {Acute myocardial infarction,Cardiogenic shock,Revascularization,IABP,MACE}, url = {http://journal.iha.org.ir/article_163881.html}, eprint = {http://journal.iha.org.ir/article_163881_5fa0b3abecb56294577f38f06256b89a.pdf} }